Semaglutide
Indication
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; or in addition to other medicinal products for the treatment of diabetes.
NICE NG28 - Type 2 diabetes in adults: management
Green
Brand:
Ozempic ®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
The GLP‑1 agonist Semaglutide is indicated in adults with type 2 diabetes mellitus to improve glycaemic control.
NICE Guideline 28 only recommends the prescribing of GLP‑1 agonists in the add-on therapy setting; therefore Semaglutide was reviewed only in the add-on therapy setting.
Semaglutide recommended as an option in line with NICE Guideline 28
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: